in its current form. SequestOx® Elite Oxycodone IR/ Tablet FDA Naltrexone Complete Response Letter indicates product is not approvable in its current form. Slide 13 Walk” “Cross Component 1: Opioids with a Heightened Public Health Risk Component 2: Interchangeable Abuse Deterrent Opioids Component 3: Walk” Chemically Equivalent Substitutions “Cross – Draft Amended Formulary Slide 14 Meeting Schedule October 21, 2016 November 18, 2016 December 16, 2016 January 20, 2017 February 17, 2017 March 17, 2017 April 20, 2017 All meetings are from 9:00AM to 12:00PM at 250 Washington Street Slide 15 Meeting Summary Meeting Recap Review of takeaways Next steps Next Meeting November 18, 2016 9:00AM-12:00PM 250 Washington Street
in its current form. SequestOx® Elite Oxycodone IR/ Naltrexone Tablet FDA Complete Response Letter indicates product is not approvable in its current form. Slide 13 “Cross Walk” Component 1: Opioids with a Heightened Public Health Risk Component 2: Interchangeable Abuse Deterrent Opioids Component 3: “Cross Walk” – Chemically Equivalent Substitutions Draft Amended Formulary Slide 14 Meeting Schedule October 21, 2016 November 18, 2016 December 16, 2016 January 20, 2017 February 17, 2017 March 17, 2017 April 20, 2017 All meetings are from 9:00AM to 12:00PM at 250 Washington Street Slide 15 Meeting Summary Meeting Recap Review of takeaways Next steps Next Meeting November 18, 2016 9:00AM-12:00PM 250 Washington Street
dfc-presentation-091516.docx